UPS Is Uniquely Positioned To Capitalize On E-Commerce Tailwinds & Drive Revenue Growth, Analyst Says
Raymond James analyst Patrick Tyler reiterated a Strong Buy rating on the shares of United Parcel Service Inc (NYSE:UPS) and lowered the…
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ:EDIT) with an Overweight rating and a price target of $15. The analyst says…
Peloton Interactive’s Q2 Should Be Good Enough To Hold Onto Gains, Says Analyst
Needham analyst Bernie McTernan reiterated a Buy rating on the shares of Peloton Interactive Inc (NASDAQ: PTON) with a price target of $14.
5 Electronic Arts Analysts On Q3 Results
Electronic Arts Inc (NASDAQ: EA) Tuesday reported disappointing third-quarter results, which sent shares down in extended trading.
Credit Suisse on Electronic Arts
Snap Is ‘A Snow Globe In A Snowstorm,’ Why Analysts Are Lowering Price Targets After Q4 Report
Social media company Snap Inc (NYSE: SNAP) reported fourth-quarter financial results after market close Tuesday. Here is what analysts are saying after the report.
General Motors Outperforms, Raises 2023 Outlook: Analysts Weigh In
General Motors Company (NYSE: GM) traded higher into Wednesay’s open after the company turned in better-than-expected financial results and raised its 2023 outlook.
Why This AMD Analyst Is Bumping Up Price Target For Stock By 19% Following Q4 Results
Advanced Micro Devices Inc.
UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline
UniQure N.V. (NASDAQ: QURE) and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
ACM Research Likely To Gain From China’s Mature Node Investment, DRAM Spend, Analyst Says
Needham analyst Quinn Bolton maintained ACM Research Inc (NASDAQ:ACMR) with a Buy and raised the price target from $10 to $12. Bolton…
Analyst Says Selecta Biosciences’ Gout Candidate Can Potentially Raise The Bar On Several Fronts
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ:SELB) from $9 to $10 while maintaining the Buy rating ahead of…